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A b s t r A c t
We report a case of a 27-year-old female with catecholaminergic polymorphic ven-
tricular tachycardia, presenting with syncope during emotional stress. Treatment 
with a β-blocker alone was ineffective, whereas the addition of amiodarone prevented 
arrhythmia-relapses for 28 months. In view of planned pregnancy, amiodarone was 
substituted with flecainide, coupled with defibrillator-implantation. Fourteen months 
later, the patient had 3 appropriate, followed by 3 inappropriate shocks. This case 
highlights the short-comings of pharmacological treatment and the limitations of 
device-therapy; the high rate of inefficacious shocks, along with the proarrhythmic 
potential, point towards the judicious use of defibrillators, aiming at shock-delivery 
only for ventricular fibrillation.
I n t r o d u c t I o n
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a primary electri-
cal disease characterized by normal resting electrocardiogram (ECG) and ventricular 
arrhythmias induced by adrenergic stress, in the absence of structural heart disease.1 
CPVT is caused by mutations in the cardiac ryanodine receptor 2 (RyR2) or in the 
sarcoplasmic reticulum protein calsequestrin-2 (CASQ2),1 which cause enhanced 
calcium release (from the sarcoplasmic reticulum) and abnormal intracellular calcium 
overload; these changes result in polymorphic ventricular tachycardia via triggered 
activity. CPVT presents invariably with syncope in children or young adults and can 
lead to sudden cardiac death.1 In patients unresponsive to pharmacological treatment, 
implantable cardioverter-defibrillators (ICDs) have been advocated,2,3 but the efficacy 
and safety of this therapy remain uncertain.
We describe a case of a young female patient with CPVT and an implanted ICD, 
who had 3 appropriate, followed by 3 inappropriate shocks during a single episode; 
after the third inappropriate shock, a couplet of premature ventricular beats was ob-
served, followed by gradual decrease of sinus rate below the (re)detection interval. If 
sustained polymorphic ventricular tachycardia had re-occurred after the sixth shock, 
the outcome might have been fatal, as the device had exhausted its therapies for a 
single episode. This case illustrates the short-comings of pharmacological treatment 
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in CPVT, and also the high rate of inefficacious shocks and 
the proarrhythmic potential of ICD-therapy.
c A s e  p r e s e n t A t I o n
A 27-year old female presented with multiple episodes of 
palpitations and dizziness, as well as with two syncopal events, 
all during intense emotional distress. She denied family history 
of sudden cardiac death. Physical examination, resting 12-lead 
ECG and echocardiography were unremarkable, but a 24-hour 
Holter recording showed sustained polymorphic ventricular 
tachycardia (VT) (Figure 1A). 
d I A g n o s t I c  e vA l u A t I o n
On admission to the University Hospital, serum electrolytes, 
troponin I and thyroid function tests were all within normal 
limits. Serial 12-lead ECGs and echocardiographic evaluations 
were normal; coronary angiography revealed normal coronary 
arteries and cardiac magnetic resonance imaging was unremark-
able. Based on these results, polymorphic VT associated with 
an acute coronary syndrome or myocarditis was excluded, as 
was structural heart disease, such as hypertrophic and dilated 
cardiomyopathies or arrhythmogenic right ventricular dysplasia.
The patient underwent maximal exercise tolerance testing, 
without signs of myocardial ischemia or ventricular arrhythmias. 
Baseline QT was normal, which shortened during exercise; 
these findings argued against short QT or long QT syndromes. 
Atrial fibrillation in the presence of an accessory pathway was 
ruled out after injection of 12 mg of adenosine, which induced 
transient complete atrio-ventricular block. Similarly, Brugada 
syndrome was ruled out based on the absence of electrocar-
diographic changes after procainamide testing at 10 mg/kg. 
An electrophysiological study showed normal conduction 
intervals, sinus node recovery time, atrio-ventricular nodal ef-
fective refractory period, retrograde atrial activation sequence 
and ventricular effective refractory period. After isoproterenol 
infusion, QT shortening was noted, thereby excluding long 
QT1.4 However, non-sustained polymorphic VT appeared 
spontaneously after isoproterenol administration; as no R-
on-T phenomenon was seen, the short-coupled variant of 
torsade de pointes was considered unlikely.5 In some runs of 
non-sustained polymorphic VT, characteristics of bidirectional 
tachycardia were noted (Figure 1B). These findings were 
considered diagnostic of CPVT, despite subsequent negative 
genotype testing results, which included mutation screening 
for RyR2 or CASQ2. 
t r e A t m e n t
Treatment with β-blockade (250 mg of metoprolol tartrate 
daily, in three divided dosages of 100 mg, 50 mg and 100 mg) 
was commenced, followed by symptomatic improvement, al-
though runs of polymorphic VT were recorded on 24-Holter 
during follow-up. However, 4 months after the initial submis-
sion, the patient was re-admitted for palpitations and syncope; 
echocardiography was again normal. Intravenous amiodarone 
was commenced, followed by oral maintenance dose at 200 mg 
daily. Due to concerns regarding ICD therapy in CPVT,6,7 ICD 
implantation was deferred and pharmacologic antiarrhythmic 
treatment was chosen. Despite the limited experience with 
amiodarone in CPVT, oral treatment was continued, with 
absence of VT recurrence for 28 months. At this point, the 
patient reported that she was contemplating pregnancy (for 
which no hormonal therapy was prescribed); in view of the 
possibility of fetal toxicity,8 amiodarone was discontinued. 
Metoprolol was continued, but amiodarone was substituted 
with flecainide 100 mg bid, based on the favorable safety 
profile of this agent during pregnancy;9 more importantly, this 
FIgure 1. Polymorphic ventricular tachycardia. Panel A: spon-
taneous polymorphic ventricular tachycardia during emotional 
stress. Panel B: ECG strip showing bidirectional ventricular 
tachycardia after isoproterenol infusion.
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treatment was selected based on early promising reports on 
the use of flecainide in patients with CPVT.10 Because of the 
absence of ventricular arrhythmias during baseline exercise 
testing, repeat testing was not used as a means of evaluating 
the efficacy of pharmacological treatment.
Given the inability to ascertain the efficacy of pharmacologi-
cal treatment by exercise testing and the relatively weak data 
on flecainide at that time, the option of defibrillator-therapy 
was proposed. The limitations of such therapy in CPVT6,7 
were explained to the patient, but she eventually underwent 
ICD implantation (Secura DR, Medtronic, Inc., Minneapolis, 
Minnesota, USA) after obtaining a second opinion. No de-
fibrillation testing was performed prior to discharge, and the 
fibrillation detection interval was programmed at 330 ms, with 
all shocks at maximum energy. A tachycardia monitor-only 
zone was programmed at 370 ms. Stability and onset criteria 
were programmed off, but PR-logic was programmed on for 
atrial flutter/fibrillation and sinus tachycardia; this algorithm 
aids in the discrimination of ventricular from supraventricular 
rhythms by monitoring the stability of the PR (or RP) intervals 
during tachycardia.
I c d  d I s c h A r g e s
Fourteen months after ICD implantation, the patient 
had a syncopal episode on exertion, while on treatment with 
flecainide and metoprolol; the patient recalled 3 ICD-shocks. 
Device interrogation (Figures 2 & 3) revealed an episode of 
polymorphic VT (Figure 2, panel a), which was not terminated 
by a 35-Joule biphasic shock. Episodes of atrial tachycardia 
were then recorded in the atrial channel (Figure 3), whereas 
the ventricular channel displayed 2 further (appropriate) 
unsuccessful shocks for polymorphic VT (Figure 2, panels b 
and c). Spontaneous termination of polymorphic VT occurred 
after the third shock (Figure 2, panel d), but sinus tachycardia 
(with frequent atrial premature depolarizations, Figure 3) 
caused 3 inappropriate shocks (Figure 2, panels e, f, g); these 
were caused by irregular ventricular intervals that fulfilled 
the redetection criteria. Of note, the device redetection algo-
rithms consider a ventricular arrhythmia event terminated if 8 
consecutive ventricular intervals longer than the programmed 
ventricular fibrillation (VF) detection interval are present 
after discharge, or when 20 seconds elapse during which the 
median of the last 12 ventricular intervals is longer than the 
FIgure 2. Device interrogation (1). Polymorphic VT (panels a, b, c), not terminated by three 35-Joule biphasic shocks. Episodes of 
non-sustained atrial tachycardia (AT) were observed after the 1st shock; VT terminated spontaneously after the 3rd shock (panel d), 
but sinus tachycardia (ST, arrow) caused 3 inappropriate shocks (panels e, f, g), followed by sinus rate lowering (ST΄) and episode 
termination (panel h). Note the couplet of premature ventricular beats (asterisks, panel h), characterized by unequal atrial (green 
double arrow) and ventricular (red double arrow) coupling intervals. Had this arrhythmia proceeded into another episode of poly-
morphic VT, this would have been untreated, because the device had exhausted its therapeutic capacity for a single episode.
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VF detection interval. After the sixth discharge, sinus heart 
rate lowered and the episode terminated (panel h). If another 
episode of polymorphic VT had occurred, this would have been 
untreated, because the device had exhausted its therapeutic 
capacity for a single episode.
To avoid therapies for polymorphic VT, the fibrillation 
detection interval was reprogrammed to 270 ms, aiming at the 
delivery of shocks only for ventricular fibrillation. In addition, 
a stability interval of 40 ms was programmed in the supraven-
tricular discriminator-algorithms. After device reprogramming, 
no further shocks occurred during an 8-month follow-up period.
d I s c u s s I o n
Our case of CPVT unfolds several features of interest in 
this rare disease. These are herein highlighted.
c l I n I c A l  p r e s e n t A t I o n  A n d  d I A g n o s I s
In our patient, CPVT was diagnosed clinically, based on 
previous criteria,1 which include adrenergically-mediated 
polymorphic or bidirectional tachycardia, in the absence of 
structural heart disease and normal ECG (absence of Brugada-
like pattern and normal QT interval at rest, during exercise 
and after isoproterenol administration). The disease was 
nongenotyped, which is in line with previous observations in 
a cohort of 30 patients,2 indicating that nongenotyped-CPVT 
is seen mostly in female patients with late presentation. In 
general, it is estimated that RyR2 or CASQ2 mutations are 
identified in only ~60% of patients presenting with a strong 
CPVT phenotype.11
A threshold heart rate (approximately 130 bpm) has been 
suggested,12 above which exercise-induced VT invariably ap-
pears in these patients, but, in our case, the conditions eliciting 
VT varied. Specifically, no VT was noted during exercise test 
(with an attained peak heart rate of 189 bpm), whereas emo-
tional stress associated with much lower sinus rates (~120 bpm) 
induced sustained polymorphic VT. This variability regarding 
threshold heart rate and precipitating conditions should be 
taken into account during clinical assessment; moreover, an 
important lesson from this case is that a negative exercise test 
does not exclude the diagnosis of CPVT. In this respect, a 
negative exercise test not only raises diagnostic difficulties, but 
also deprives a simple means of evaluating the pharmacological 
regimens during follow-up.
t r e A t m e n t
β-Blockade remains the mainstay treatment in CPVT, but 
it may prove ineffective in ~30% of cases.1,2 Amiodarone exerts 
potent antiarrhythmic actions via all known pharmacologic 
mechanisms, but there is no published experience with the use 
of this agent in CPVT. In our patient, oral amiodarone (at 200 
mg daily) was associated with absence of arrhythmia recur-
rence during a 28-month follow-up period. Thus, amiodarone 
added to β-blockade appears effective in CPVT resistant to 
monotherapy, although more data are needed; nonetheless, 
the non-cardiac side-effect profile of amiodarone should be 
taken into account, especially in young patients, including 
females in child-bearing age.
Flecainide decreases spontaneous calcium-release from the 
sarcoplasmic reticulum by cardiac ryanodine receptor inhibi-
tion, but also suppresses triggered beats by sodium-channel 
blockade.10 The efficacy of this agent has been confirmed in 
33 patients with genotype-positive13 and in 12 patients with 
FIgure 3. Device interrogation (2). Summary of the entire arrhythmic event marked with a time-scale. Note the four polymorphic 
ventricular tachycardia episodes (the last of which terminated spontaneously prior to shock delivery) and the ensuing sinus tachycar-
dia with frequent atrial premature depolarizations, causing inappropriate shocks.
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genotype-negative CPVT.14 Arrhythmia relapses occurred 
in 1 patient (3%) over (a median of) 20 months in the first 
series13 and in 2 patients (16%) over (a mean of) 48 months 
in the second series,14 possibly due to noncompliance in all 
three. In our patient, flecainide (200 mg daily) suppressed 
ventricular arrhythmias initially, but VT relapse occurred 14 
months after treatment initiation, despite adequate compliance 
to the drug regimen. 
d e v I c e  t h e r A p y
ICD implantation has been suggested in patients unrespon-
sive to medical treatment.2 In a report of 20 pediatric patients 
with symptomatic CPVT,3 failure of high-dose β-blockade was 
recorded in 13 patients; of these, 8 refused ICDs, and eventu-
ally 6 (75%) died suddenly. However, the pattern of electrical 
storm not terminated by recurrent ICD shocks described in our 
patient was observed in 4 of the 5 patients who received ICDs 
in this cohort;3 as in our patient, these VT-storms terminated 
spontaneously after delivery of the programmed ICD shocks, 
without degeneration to ventricular fibrillation. By contrast, 
fatal outcome of electrical storm has been reported in 2 
other patients with CPVT and implanted defibrillators.6,7 The 
mechanism is thought to be catecholamine release, mediated by 
shocks, triggering a vicious cycle of VT and device discharges. 
In our patient, the examination of stored electrograms 
by the device and the overview of the detection intervals add 
more information on device (and pharmacological) therapy in 
CPVT. Specifically, four points should be noted.
(a) As in a recently reported case of a 22-year-old pa-
tient with CPVT,15 our patient had 3 unsuccessful shocks for 
polymorphic VT. Whether this represents high defibrillation 
threshold in these patients or whether the arrhythmia re-
initiates immediately after the shock cannot be accurately 
determined and requires further investigation. Defibrillation 
testing post-implantation may be useful in this regard.
(b) High sinus rate was observed after VT termination, 
despite β-blockade at high dosages, interfering with the ar-
rhythmia-detection process by the device, and similar findings 
were reported previously in a patient receiving 300 mg of 
atenolol.7 Thus, ‘ultra-high’ dosages of β-blockers have been 
recommended in CPVT patients, with the possible addition of 
verapamil.7 In cases of positive baseline exercise testing, repeat 
testing should be used during follow-up to ascertain adequate 
response to pharmacologic treatment.7
(c) A subset of CPVT-patients have also catecholamine-
induced atrial arrhythmias,16 which cause further interference 
with VT detection by the device.7 Although repeated 24-hour 
Holter recordings failed to reveal atrial arrhythmias in our 
patient, episodes of non-sustained atrial tachycardia were 
observed after the first shock; thus, the prevention of atrial ar-
rhythmias and lowering the ventricular response are additional 
therapeutic targets in CPVT patients, even in the absence of 
clinical manifestations.
(d) A different ICD-programming strategy should be 
employed in CPVT, compared to other indications; due to 
frequent VT recurrences after ICD shocks, ICD therapy in 
CPVT should be targeted at prompt defibrillation, in cases 
of degeneration of polymorphic VT to ventricular fibrillation. 
This implies programming the fibrillation detection interval to 
sufficiently low values, thereby preventing not only inappro-
priate shocks, but also device-therapies for polymorphic VT. 
l e F t  c A r d I A c  s y m pA t h e t I c  d e n e r vA t I o n
Pharmacological antiarrhythmic therapy is of paramount 
importance in CPVT, but in drug-resistant cases sympathetic 
denervation should be contemplated; this treatment can be 
performed without significant complications and has been 
shown to reduce arrhythmia recurrences.17 
c o n c l u s I o n
Our case illustrates the short-comings of pharmacologi-
cal treatment in CPVT during long-term follow-up, but also 
emphasizes the limitations of ICD therapy; the high rate of 
inefficacious shocks, along with the proarrhythmic potential, 
point towards the judicious use of this therapy. In implanted 
devices, meticulous programming is required to prevent inap-
propriate shocks. Left cardiac sympathetic denervation may 
be a viable therapeutic alternative in such cases.
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